Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TrkB partial agonists: potential treatment strategy for major depression.

Shih-Jen Tsai1

  • 1Department of Psychiatry, Taipei Veterans General Hospital, 201 Shih-Pai Road, Sec. 2, 11217 Taipei, Taiwan. sjtsai@vghtpe.gov.tw

Medical Hypotheses
|August 15, 2006
PubMed
Summary

Novel antidepressants may target the brain-derived neurotrophic factor (BDNF) and its receptor TrkB. Partial agonists for TrkB offer a potential strategy for major depression by modulating BDNF activity in specific brain regions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional MRI and <i>ApoE4</i> genotype for predicting cognitive decline in amyloid-positive individuals.

Therapeutic advances in neurological disorders·2022
Same author

Risk of Major Mental Disorder after Severe Bacterial Infections in Children and Adolescents: A Nationwide Longitudinal Study.

Neuropsychobiology·2022
Same author

Parental post-traumatic stress disorder and increased risk of chronic pain conditions and major psychiatric disorders in their offspring.

General hospital psychiatry·2022
Same author

A longitudinal study of the association between pro-inflammatory cytokines and mood symptoms in bipolar disorder.

Acta psychiatrica Scandinavica·2022
Same author

Role of Appetite Hormone Dysregulation in Symptomology and Executive Function in Adolescents With Attention Deficit Hyperactivity Disorder.

The international journal of neuropsychopharmacology·2022
Same author

Association between parental bipolar disorder and increased risk of exposure to prescription opioids for their offspring.

Social psychiatry and psychiatric epidemiology·2022

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Brain-derived neurotrophic factor (BDNF) is crucial for nervous system development, function, and survival via the tyrosine kinase B receptor (TrkB).
  • Dysregulation of the BDNF-TrkB pathway, particularly reduced activity in the hippocampus, is implicated in major depressive disorder (MDD) pathophysiology.
  • Conversely, elevated BDNF activity in the mesolimbic region may contribute to depressive states.

Purpose of the Study:

  • To explore the therapeutic potential of TrkB partial agonists for major depression.
  • To investigate the hypothesis that differential BDNF activity in the hippocampus and mesolimbic system contributes to MDD.
  • To propose a strategy for developing novel antidepressants based on regional BDNF-TrkB modulation.

Main Methods:

  • Review of existing literature on BDNF, TrkB signaling, and major depression.

Related Experiment Videos

  • Analysis of the dual role of BDNF in different brain regions (hippocampus vs. mesolimbic).
  • Consideration of small peptide TrkB partial agonists.

    • Main Results:

    • BDNF may exert opposing effects in different brain regions, being antidepressant in the hippocampus and pro-depressive in the mesolimbic system.
    • TrkB partial agonists can elicit a submaximal response, potentially balancing regional BDNF activity.
    • A selective hippocampus/mesolimbic BDNF activation ratio is proposed as a key factor for antidepressant efficacy.

    Conclusions:

    • TrkB partial agonists represent a novel therapeutic strategy for major depression.
    • Targeting the imbalance of BDNF-TrkB signaling in specific brain regions may be crucial for effective antidepressant development.
    • Optimizing the hippocampus/mesolimbic activation ratio of agents targeting the BDNF-TrkB pathway could lead to improved treatments for MDD.